Header Logo
Keywords
Last Name
Institution
Announcement

You can now add alternative names! Click here to add other names that you've published under.
Back to Search Results

Connection

Search Results to Frits Van Rhee

This is a "connection" page, showing the details of why an item matched the keywords from your search.

                     
                     

One or more keywords matched the following items that are connected to Van Rhee, Frits

Item TypeName
Academic Article Treatment advances in multiple myeloma.
Academic Article A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.
Academic Article Allografting or autografting for myeloma.
Academic Article Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
Academic Article Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3.
Academic Article Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.
Academic Article Mobilization of peripheral blood stem cells in myeloma with either pegfilgrastim or filgrastim following chemotherapy.
Academic Article A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease.
Academic Article Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.
Academic Article High-dose melphalan-based autotransplants for multiple myeloma: the Arkansas experience since 1989 in 3077 patients.
Concept Antineoplastic Agents
Concept Antineoplastic Agents, Alkylating
Concept Antineoplastic Agents, Hormonal
Academic Article Siltuximab for multicentric Castleman disease.
Academic Article Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.
Academic Article A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease.
Academic Article Treatment of Idiopathic Castleman Disease.
Academic Article Daratumumab for POEMS Syndrome.
Academic Article Infectious and immunological sequelae of daratumumab in multiple myeloma.
Academic Article International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
Academic Article Lack of Spleen Signal on Diffusion Weighted MRI is associated with High Tumor Burden and Poor Prognosis in Multiple Myeloma: A Link to Extramedullary Hematopoiesis?
Academic Article Long-term safety of siltuximab in patients with idiopathic multicentric Castleman disease: a prespecified, open-label, extension analysis of two trials.
Academic Article Newly diagnosed and previously treated multicentric Castleman disease respond equally to siltuximab.
Academic Article International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
Academic Article Clinical efficacy of sequencing CD38 targeting monoclonal antibodies in relapsed refractory multiple myeloma: A multi-institutional experience.
Academic Article Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study.

Search Criteria
  • Antineoplastic Agents